MGM Healthcare, a leading quaternary care hospital in Chennai, has created the world’s largest intestinal rehabilitation and transplant program from scratch—achieving in three years what usually takes decades. 

 

Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone, the highest annual volume recorded anywhere globally.

 

The ambitious program was spearheaded by Dr. Anil Vaidya, Chair and Director of the Institute of Multi-Visceral and Abdominal Organ Transplant, after his return from the Cleveland Clinic in the United States. 

 

He led a multidisciplinary team—including Dr. Senthil Muthuraman, Dr. Venkatesh BS, Dr. Sivakumar Mahalingam, and Dr. Manoj Prabhakar—working alongside intensivists and anaesthetists Dr. C. P. Dinesh Babu, Late Dr. Nivash Chandrashekar, and Dr. Saravanan to build a comprehensive program spanning surgery, rehabilitation, home-based care, and long-term monitoring.

 

“Intestinal rehabilitation and transplantation is among the most complex and resource-intensive domains in medicine. It replaces the failing intestine with a donor organ, restoring the body’s ability to absorb nutrients naturally. 

 

"By building the world’s largest program in this domain, we have positioned Chennai as a global reference point. This was not just about creating a transplant program, but an integrated ecosystem spanning surgery, rehabilitation, home-based care, infection control, and long-term monitoring,” Dr. Vaidya said.

 

The program boasts world-class one- and three-year survival rates, often exceeding outcomes at leading centers in the United States and Europe. But success is measured not just by surgical survival—it is defined by freedom from total parenteral nutrition (TPN), immune stability, and functional recovery. Today, 98% of patients are free from TPN, a milestone that signals true physiological recovery and a return to normal life.

 

Beyond scale and outcomes, the program is breaking new ground in intestinal transplantation. It launched India’s first Transplant Oncology program and the world’s third of its kind, offering intestinal transplantation as a curative option for patients with inoperable pseudomyxoma peritonei. 

 

Dr. Vaidya explained, “This represents a paradigm shift: moving transplantation beyond organ failure into the domain of complex malignancy, where conventional surgical options are exhausted. For a disease historically considered terminal in its advanced stages, this approach opens a new therapeutic frontier.”

 

He highlighted three defining innovations at the core of the program’s success:

 

I. A robust, home-based TPN (HPN) program, supporting patients outside hospital settings.

 

II. A novel, patented antiseptic solution, Dorbimex, used for central line care, which, combined with strict protocols, has driven central line infection rates to near zero.

 

III. A specialized critical care transport network—the “Back to Base” model—allowing safe transfer of patients with acute intestinal loss from across India, including Mumbai, Delhi, Agra, Kolkata, and Goa, via air, road, and even train-based transport.

 

“Intestinal failure is a systems problem, requiring synchronized expertise across nutrition, immunology, infection control, critical care, and surgery. What has emerged is more than a clinical program—it reflects how high-complexity care can be thoughtfully designed and scaled in India. 

 

"It also underscores that innovation in care delivery, not just technology, is critical to improving outcomes, and that leadership in advanced medicine is no longer limited by geography,” Dr. Vaidya said.